Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AnPAF: Antazoline in Paroxysmal Atrial Fibrillation
NCT01527279Phase 4Completed
- Sponsor
- National Institute of Cardiology
- Start
- Nov 2012
- Primary completion
- Jan 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in Atrial fibrillation (AFib) comparing Antazoline with Placebo (2 arms). Primary endpoint: Conversion of atrial fibrillation to sinus rhythm at 1.5 hours. Started Nov 2012; status: completed.
02
Drugs
antazoline
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT01527279.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01527279.